These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

436 related items for PubMed ID: 28858531

  • 1. An update on cladribine for relapsing-remitting multiple sclerosis.
    Holmøy T, Torkildsen Ø, Myhr KM.
    Expert Opin Pharmacother; 2017 Oct; 18(15):1627-1635. PubMed ID: 28858531
    [Abstract] [Full Text] [Related]

  • 2. Cladribine for multiple sclerosis.
    Drug Ther Bull; 2018 Feb; 56(2):21-24. PubMed ID: 29449328
    [Abstract] [Full Text] [Related]

  • 3. Safety and tolerability of cladribine tablets in multiple sclerosis: the CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) study.
    Cook S, Vermersch P, Comi G, Giovannoni G, Rammohan K, Rieckmann P, Sørensen PS, Hamlett A, Miret M, Weiner J, Viglietta V, Musch B, Greenberg SJ, CLARITY Study Group.
    Mult Scler; 2011 May; 17(5):578-93. PubMed ID: 21228029
    [Abstract] [Full Text] [Related]

  • 4. Long-term management of multiple sclerosis patients treated with cladribine tablets: an expert opinion.
    Meuth SG, Bayas A, Kallmann B, Kleinschnitz C, Linker R, Rieckmann P, Mäurer M.
    Expert Opin Pharmacother; 2020 Nov; 21(16):1965-1969. PubMed ID: 32658554
    [Abstract] [Full Text] [Related]

  • 5. Cladribine tablets: a potential new short-course annual treatment for relapsing multiple sclerosis.
    Sipe JC.
    Expert Rev Neurother; 2010 Mar; 10(3):365-75. PubMed ID: 20187859
    [Abstract] [Full Text] [Related]

  • 6. Cladribine tablets for the treatment of relapsing-remitting multiple sclerosis.
    Comi G, Hartung HP, Kurukulasuriya NC, Greenberg SJ, Scaramozza M.
    Expert Opin Pharmacother; 2013 Jan; 14(1):123-36. PubMed ID: 23256518
    [Abstract] [Full Text] [Related]

  • 7. Safety of cladribine tablets in the treatment of patients with multiple sclerosis: An integrated analysis.
    Cook S, Leist T, Comi G, Montalban X, Giovannoni G, Nolting A, Hicking C, Galazka A, Sylvester E.
    Mult Scler Relat Disord; 2019 Apr; 29():157-167. PubMed ID: 30885374
    [Abstract] [Full Text] [Related]

  • 8. Cladribine tablets' potential in multiple: sclerosis treatment.
    Costello K, Sipe JC.
    J Neurosci Nurs; 2008 Oct; 40(5):275-80. PubMed ID: 18856248
    [Abstract] [Full Text] [Related]

  • 9. Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis.
    Giovannoni G, Cook S, Rammohan K, Rieckmann P, Sørensen PS, Vermersch P, Hamlett A, Viglietta V, Greenberg S, CLARITY study group.
    Lancet Neurol; 2011 Apr; 10(4):329-37. PubMed ID: 21397565
    [Abstract] [Full Text] [Related]

  • 10. [Oral cladribine for relapsing-remitting multiple sclerosis: another purine analogue or a genuine therapeutic innovation?].
    Schmidt S.
    Nervenarzt; 2010 Oct; 81(10):1231-41. PubMed ID: 20567960
    [Abstract] [Full Text] [Related]

  • 11. Cost-effectiveness of cladribine tablets, alemtuzumab, and natalizumab in the treatment of relapsing-remitting multiple sclerosis with high disease activity in England.
    Hettle R, Harty G, Wong SL.
    J Med Econ; 2018 Jul; 21(7):676-686. PubMed ID: 29618273
    [Abstract] [Full Text] [Related]

  • 12. Emerging oral drugs for relapsing-remitting multiple sclerosis.
    Gasperini C, Ruggieri S.
    Expert Opin Emerg Drugs; 2011 Dec; 16(4):697-712. PubMed ID: 22148963
    [Abstract] [Full Text] [Related]

  • 13. Promising outcomes from Phase III CLARITY study for the treatment of multiple sclerosis announced.
    Expert Rev Pharmacoecon Outcomes Res; 2009 Jun; 9(3):198. PubMed ID: 19527090
    [No Abstract] [Full Text] [Related]

  • 14. Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study.
    Giovannoni G, Soelberg Sorensen P, Cook S, Rammohan K, Rieckmann P, Comi G, Dangond F, Adeniji AK, Vermersch P.
    Mult Scler; 2018 Oct; 24(12):1594-1604. PubMed ID: 28870107
    [Abstract] [Full Text] [Related]

  • 15. Cladribine: mode of action and implications for treatment of multiple sclerosis.
    Leist TP, Weissert R.
    Clin Neuropharmacol; 2011 Oct; 34(1):28-35. PubMed ID: 21242742
    [Abstract] [Full Text] [Related]

  • 16. Effects of Postponing Treatment in the Second Year of Cladribine Administration: Clinical Trial Simulation Analysis of Absolute Lymphocyte Counts and Relapse Rate in Patients with Relapsing-Remitting Multiple Sclerosis.
    Terranova N, Hicking C, Dangond F, Munafo A.
    Clin Pharmacokinet; 2019 Mar; 58(3):325-333. PubMed ID: 29992396
    [Abstract] [Full Text] [Related]

  • 17. Orally administered cladribine displays efficacy in multiplesclerosis trial.
    Yates D.
    Nat Rev Neurol; 2010 Apr; 6(4):182. PubMed ID: 20383882
    [No Abstract] [Full Text] [Related]

  • 18. Impact of Nonrandomized Dropout on Treatment Switching Adjustment in the Relapsing-Remitting Multiple Sclerosis CLARITY Trial and the CLARITY Extension Study.
    Gorrod HB, Latimer NR, Damian D, Hettle R, Harty GT, Wong SL.
    Value Health; 2019 Jul; 22(7):772-776. PubMed ID: 31277823
    [Abstract] [Full Text] [Related]

  • 19. Identification of targets and new developments in the treatment of multiple sclerosis--focus on cladribine.
    Warnke C, Wiendl H, Hartung HP, Stüve O, Kieseier BC.
    Drug Des Devel Ther; 2010 Jul 21; 4():117-26. PubMed ID: 20689698
    [Abstract] [Full Text] [Related]

  • 20. CLICK-MS and MASTER-2 Phase IV trial design: cladribine tablets in suboptimally controlled relapsing multiple sclerosis.
    Miravalle AA, Katz J, Robertson D, Hayward B, Harlow DE, Lebson LA, Sloane JA, Bass AD, Fox EJ.
    Neurodegener Dis Manag; 2021 Apr 21; 11(2):99-111. PubMed ID: 33517769
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.